Literature DB >> 2770950

Impaired renal hemodynamic but conserved natriuretic response to dopamine in patients with renal disease.

A J Smit1, S Meijer, H Wesseling, W D Reitsma, A J Donker.   

Abstract

Renal hemodynamics and sodium excretion were determined before and during infusion of dopamine in doses ranging from 0.25 to 8 micrograms/kg/min in healthy volunteers (n = 15) and in patients with renal disease and moderately impaired renal function (n = 21, baseline glomerular filtration rate 34-85 ml/min). While in normal volunteers dopamine resulted in marked renal vasodilation (maximal fall in filtration fraction 24%), in patients with moderately impaired renal function, the renal vasodilatory response to dopamine was impaired (maximal fall in FF 13%) and was found to depend on baseline glomerular filtration rate. Infusion of dopamine in doses of 2 micrograms/kg/min and higher resulted in an increase in urinary sodium excretion, which was comparable for healthy volunteers and patients with renal disease. We conclude that dopamine results in a predominantly efferent glomerular vasodilation and, therefore, may be salutary in lowering intraglomerular hypertension. However, in patients with renal disease the renal hemodynamic response to dopamine infusion is impaired compared to healthy volunteers, while the natriuretic response is maintained.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2770950     DOI: 10.1159/000185674

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

1.  The effects of alpha-adrenoceptor blockade on dopamine-induced renal vasodilation and natriuresis.

Authors:  A J Smit; S Meijer; H Wesseling; A J Donker; W D Reitsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

2.  Dissociation of renal vasodilator and natriuretic effects of dopamine during sulpiride infusion in normal man.

Authors:  A J Smit; S Meijer; H Wesseling; A J Donker; W D Reitsma
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.